子宫腺肌症治疗方法及效果研究现状
|
摘要
子宫腺肌症(adenomysis AM)临床上多以经期疼痛进行性加重、月经量过多、子宫内膜增厚等为主要表现,可对患者的生活质量产生严重影响。目前对于子宫腺肌症的发病机制尚不明确,临床上治疗以缓解经期疼痛、减少月经量、抑制子宫内膜增厚为主要治疗目标,常用的治疗方法有手术治疗及药物治疗,临床上最常用的是曼月乐治疗,本文就此对子宫腺肌症的治疗方法及相关研究做一重点综述,为子宫腺肌症的以后临床治疗提供参考。
Adenomis AM(adenomis AM) is clinically mainly manifested in menstrual pain, excessive menstruation, and thickening of the endometrium, which can have a serious impact on the quality of life of patients. At present, the pathogenesis of uterine adenomyosis is not yet clear. Therefore, in the treatment of uterine adenomyosis, the goal of treatment is to relieve menstrual pain, reduce the amount of menstruation, and inhibit the thickening of the endometrium. Currently, the commonly used treatment methods are surgical treatment and drug treatment. At present, the most commonly used is manyuele treatment, this article on the treatment of uterine adenomyosis and related studies to make a focus of a review, for the later clinical treatment of uterine adenomyosis to provide a reference.
Adenomis AM(adenomis AM) is clinically mainly manifested in menstrual pain, excessive menstruation, and thickening of the endometrium, which can have a serious impact on the quality of life of patients. At present, the pathogenesis of uterine adenomyosis is not yet clear. Therefore, in the treatment of uterine adenomyosis, the goal of treatment is to relieve menstrual pain, reduce the amount of menstruation, and inhibit the thickening of the endometrium. Currently, the commonly used treatment methods are surgical treatment and drug treatment. At present, the most commonly used is manyuele treatment, this article on the treatment of uterine adenomyosis and related studies to make a focus of a review, for the later clinical treatment of uterine adenomyosis to provide a reference.
引文
[1]杨慧霞,狄文.子宫腺肌病[M].第一版,妇产科学,2016:403.
[2]Lindh I,Milsom I.The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea:a longitudinal population study[J].Hum Reprod,2013,28(7):1953-1960
[3]周蕊敏.曼月乐环治疗子宫腺肌症的临床疗效观察[J].实用妇科内分泌电子杂志,20141(4):9-11.
[4]李环,魏洪,佘昌明,等.134例子宫全切除术后患者盆底功能影响的调查[J].中华全科医学,2014,12(3):422-423,431
[5]翟栋材,张申杰,张博,等.超声造影与增强MRI评价聚焦超声消融治疗子宫腺肌症的对照研究[J].山东大学学报(医学版),2014,52(z1):112-113.
[6]肖斌梅.腹腔镜子宫切除术治疗子宫腺肌症的临床分析[J].中国现代医生,2020,48(24):242-243.
[7]阮立勤.腹腔镜子宫切除术与传统子宫切除术的临床效果探讨[J].河北医学,2023,19(3):413-413.
[8]任红云,黄云,毛惠,等.全子宫切除术三种术式的比较研究[J].昆明医学院学报,2020,32(22):226-228.
[9]杨娟.腹腔镜子宫切除术治疗子宫腺肌症的临床疗效分析[J].中国卫生标准管理,2016,7(17):42-43.
[10]BRATBY MJ,WALKER WJ.Uterine artery embolization for symptomatic adenomyosis-mid-term results[J].Eur J Radiol,2009,70(1):128-132.
[11]POPOVIC M,PUCHNERS,BERZACZYD,etal.Uterine artery embolization for the treatment of adenomyosis:a review[J].J Vasc Interv Radiol,2011,22(7):901-909.
[12]杨欣,王晓娜,胡美丽,等.高强度聚焦超声消融子宫腺肌症48例临床疗效观察[J].河北医科大学学报,2016,37(1):83-86.
[13]Cheng C,Xiao Z,Huang G,etal.Enhancing ablation effects of a microbubble:Contrast agent on high-intensity focused ultrasound:An enexperimental and clinical study[J].BJOG,2017,124(Supp13):78-86.
[14]王玉,杨清,顾雪桥.左炔诺孕酮宫内缓释系统预防子宫内膜异位症术后复发的疗效[J].中国医科大学学报,2017,46(9):812-815.
[15]张明芳,戴红春.左炔诺孕酮宫内缓释系统和复方口服避孕药用于卵巢子宫内膜异位症患者复发后的治疗效果[J].中国当代医药,2016,23(26):58-60.
[16]杭悦霞,李娟.左炔诺孕酮宫内缓释系统预防子宫内膜异位症保守性手术后复发的疗效观察[J].中国妇产科临床杂志,2016,7(2):160-162.
[17]郝莹莹,谷瑞东,林蓓等.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床观察[J].实用药物与临床杂志,2008,11(2):77-78.
[18]李莉莎,温思思,甘海英.GnRHa亮丙瑞林联合曼月乐环保守治疗子宫腺肌症38例临床分析[J].药品评价,2016,13(20):50-51+60.
[19]赵霞,方向明.醋酸亮丙瑞林预处理联合腹腔镜下子宫肌瘤剔除术治疗巨大子宫肌瘤临床观察[J].中华全科医学,2015,13(8):1293-1295.
[20]李宝萍.醋酸亮丙瑞林联合腹腔镜切除病灶治疗子宫腺肌症的疗效及不良反应[J].实用医学杂志,2016,32(3):502-503.
[21]刘丽新.曼月乐治疗无排卵性功血的疗效观察[J].实用妇科内分泌电子杂志,2016,3(8):78.
[22]张建云.曼月乐治疗功能失调性子宫出血60例临床观察[J].临床医药文献电子杂志,2016,3(51):10214-10215.
[23]范光升,卞美璐,程利南,等.新型口服避孕药屈螺酮炔雌醇片的多中心随机对照临床观察[J].中华妇产科杂志,2009,44(1):38-40.
[24]邹党华,蔡建红.曼月乐配伍屈螺酮炔雌醇片治疗子宫腺肌症的安全性分析[J].基层医学论坛,2013,17(34):4581-4582.
[25]幸福花.二甲双胍联合达英-35治疗多囊卵巢综合征53例临床疗效观察[J].吉林医学,2018,39(09):1714-1715.
[2]Lindh I,Milsom I.The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea:a longitudinal population study[J].Hum Reprod,2013,28(7):1953-1960
[3]周蕊敏.曼月乐环治疗子宫腺肌症的临床疗效观察[J].实用妇科内分泌电子杂志,20141(4):9-11.
[4]李环,魏洪,佘昌明,等.134例子宫全切除术后患者盆底功能影响的调查[J].中华全科医学,2014,12(3):422-423,431
[5]翟栋材,张申杰,张博,等.超声造影与增强MRI评价聚焦超声消融治疗子宫腺肌症的对照研究[J].山东大学学报(医学版),2014,52(z1):112-113.
[6]肖斌梅.腹腔镜子宫切除术治疗子宫腺肌症的临床分析[J].中国现代医生,2020,48(24):242-243.
[7]阮立勤.腹腔镜子宫切除术与传统子宫切除术的临床效果探讨[J].河北医学,2023,19(3):413-413.
[8]任红云,黄云,毛惠,等.全子宫切除术三种术式的比较研究[J].昆明医学院学报,2020,32(22):226-228.
[9]杨娟.腹腔镜子宫切除术治疗子宫腺肌症的临床疗效分析[J].中国卫生标准管理,2016,7(17):42-43.
[10]BRATBY MJ,WALKER WJ.Uterine artery embolization for symptomatic adenomyosis-mid-term results[J].Eur J Radiol,2009,70(1):128-132.
[11]POPOVIC M,PUCHNERS,BERZACZYD,etal.Uterine artery embolization for the treatment of adenomyosis:a review[J].J Vasc Interv Radiol,2011,22(7):901-909.
[12]杨欣,王晓娜,胡美丽,等.高强度聚焦超声消融子宫腺肌症48例临床疗效观察[J].河北医科大学学报,2016,37(1):83-86.
[13]Cheng C,Xiao Z,Huang G,etal.Enhancing ablation effects of a microbubble:Contrast agent on high-intensity focused ultrasound:An enexperimental and clinical study[J].BJOG,2017,124(Supp13):78-86.
[14]王玉,杨清,顾雪桥.左炔诺孕酮宫内缓释系统预防子宫内膜异位症术后复发的疗效[J].中国医科大学学报,2017,46(9):812-815.
[15]张明芳,戴红春.左炔诺孕酮宫内缓释系统和复方口服避孕药用于卵巢子宫内膜异位症患者复发后的治疗效果[J].中国当代医药,2016,23(26):58-60.
[16]杭悦霞,李娟.左炔诺孕酮宫内缓释系统预防子宫内膜异位症保守性手术后复发的疗效观察[J].中国妇产科临床杂志,2016,7(2):160-162.
[17]郝莹莹,谷瑞东,林蓓等.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床观察[J].实用药物与临床杂志,2008,11(2):77-78.
[18]李莉莎,温思思,甘海英.GnRHa亮丙瑞林联合曼月乐环保守治疗子宫腺肌症38例临床分析[J].药品评价,2016,13(20):50-51+60.
[19]赵霞,方向明.醋酸亮丙瑞林预处理联合腹腔镜下子宫肌瘤剔除术治疗巨大子宫肌瘤临床观察[J].中华全科医学,2015,13(8):1293-1295.
[20]李宝萍.醋酸亮丙瑞林联合腹腔镜切除病灶治疗子宫腺肌症的疗效及不良反应[J].实用医学杂志,2016,32(3):502-503.
[21]刘丽新.曼月乐治疗无排卵性功血的疗效观察[J].实用妇科内分泌电子杂志,2016,3(8):78.
[22]张建云.曼月乐治疗功能失调性子宫出血60例临床观察[J].临床医药文献电子杂志,2016,3(51):10214-10215.
[23]范光升,卞美璐,程利南,等.新型口服避孕药屈螺酮炔雌醇片的多中心随机对照临床观察[J].中华妇产科杂志,2009,44(1):38-40.
[24]邹党华,蔡建红.曼月乐配伍屈螺酮炔雌醇片治疗子宫腺肌症的安全性分析[J].基层医学论坛,2013,17(34):4581-4582.
[25]幸福花.二甲双胍联合达英-35治疗多囊卵巢综合征53例临床疗效观察[J].吉林医学,2018,39(09):1714-1715.